Skip to content

HPV DNA Self-sampling in a General Practitioner's Office.

Benefit of Self-sampling for HPV DNA in a General Practitioner's Office to Improve Participation in Cervical Screening - The ASTRA Study.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06253169
Acronym
ASTRA
Enrollment
2000
Registered
2024-02-12
Start date
2024-03-01
Completion date
2025-06-30
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer, HPV Infection, Precancerous Lesion

Keywords

Prevention, Cervical cancer, HPV test, Self-sampling

Brief summary

One of the limitations of organized cervical screening in the Czech Republic is the lack of participation in preventive gynecological examinations. The aim of the project is to evaluate the benefits of self-sampling for HPV DNA in general practitioners' outpatient clinics to improve population participation in cervical screening.

Detailed description

Organized cervical screening in the Czech Republic has a long-term participation rate of about 56% of the target population. Despite active invitations through health insurance companies, a part of the population is resistant and does not participate in screening visits to gynaecologists in the long term. A significant proportion of such women, however, regularly visit their general practitioner due to other comorbidities. The aim of the ASTRA project is to assess whether an effective way to increase the proportion of women attending cervical screening is to perform self-testing for HPV DNA in the GP's office.

Interventions

DIAGNOSTIC_TESTHPV DNA self-test

HPV DNA swab from the cervix performed by the patient herself.

Sponsors

Patient Organization Veronica
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Signed informed consent for statistical data processing and consent to the processing of personal data * Age 30+ * HPV test never performed or performed more than 3 years ago or patient does not know

Exclusion criteria

* Refusal to participate * Pregnancy and puerperium * Menses * History of hysterectomy * HPV test performed \<3 years ago with negative result * Regular participation in screening and concurrent age 35, 45 or 55 years (test will be performed in the same year of screening).

Design outcomes

Primary

MeasureTime frameDescription
To assess response rates to being approached about the possibility of self-testing for HPV in both study cohorts and overall.Through study completion, an average of 1 yearTo compare the proportion of women who self-test for HPV DNA in a GP office versus those who refuse to take the test. To assess the overall proportion of women who self-test and the proportion in each study cohort.
Evaluation of the frequency of positivity of the HPV tests taken.Through study completion, an average of 1 yearCompare the proportion of women who will self-test positive for HPV DNA, including an assessment of positivity for HPV 16/18 and other HPV genotypes. To assess the overall proportion of women testing positive and the proportion in each study cohort.
Evaluation of follow-up gynaecological care in women who tested positive.Through study completion, an average of 1 yearTo assess what proportion of women who self-test positive for HPV DNA will accept a gynecologic exam and to assess the results of the gynecologic visit.

Countries

Czechia

Contacts

Primary ContactJiří Sláma, MD, PhD
jiri.slama@vfn.cz+420224967451

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026